Labaran Kamfani
Ingancin Tsawon Lokaci na CD19 CAR T-Cell Therapy a cikin Magance Ciwon Ciwon Ciwon Ciwon Ciwon Jiya
Wani bincike mai zurfi ya nuna nasarar da aka samu na CD19 CAR T-cell therapy a cikin kula da marasa lafiya tare da ciwon sankarar jini mai tsanani / refractory m lymphoblastic leukemia (ALL) bin allogeneic hematopoietic stem cell transplantation, yana ba da sabon bege a cikin ilimin halittar jini.
Bioocus yana Ci gaban gaba a cikin Maganin Cutar sankarar mahaifa mai Mugun Lymphoblastic
Bioocus yana kan gaba wajen haɓaka hanyoyin CAR-T masu zuwa. Buga na baya-bayan nan da Dokta Chunrong Tong da tawagarta a asibitin Lu Daopei suka buga ya nuna muhimman ci gaba da kalubale a cikin aikace-aikacen jiyya na CD19 CAR-T na ƙarni na biyu a cikin marasa lafiya na yara, yana nuna sadaukarwar Bioocus ga sabbin hanyoyin magance cutar kansa.
Maganin CAR-T na Majagaba a cikin B-cell Cute Lymphoblastic Leukemia yana Nuna Ƙarfin da Ba'a taɓa samu ba
Wani bincike mai ban sha'awa yana nuna tasiri mai ban mamaki na CAR-T cell far a cikin maganin cutar sankarar bargo na B-cell Acute Lymphoblastic Leukemia (B-ALL). Binciken, wanda ya haɗa da haɗin gwiwa tare da BOOCUS da asibitin Lu Daopei, ya nuna ci gaba mai mahimmanci, kafa farfagandar a matsayin zaɓi mai mahimmanci.
Sabbin hanyoyin CAR-T na Kwayoyin Halitta suna Canza Jiyya na Malignancin Kwayoyin B
Masu bincike daga Asibitin Lu Daopei da masu haɗin gwiwa na kasa da kasa sun bincika manyan hanyoyin kwantar da hankali na CAR-T, suna ba da bege ga marasa lafiya da ke da cututtukan ƙwayoyin cuta. Wannan binciken yana nuna ci gaba a cikin ƙira da aikace-aikace, yana nuna sakamako masu ban sha'awa da yuwuwar sabbin abubuwa na gaba.
Ingantattun Tasirin Antitumor na 4-1BB-Tsashen CD19 CAR-T Kwayoyin a Magance B-ALL
Nazarin asibiti na baya-bayan nan ya nuna cewa sel CD19 na CAR-T na 4-1BB suna nuna ingantaccen ingancin antitumor idan aka kwatanta da sel CAR-T na tushen CD28 a cikin maganin sake dawowa ko refractory B cell m lymphoblastic leukemia (r/r B-ALL).
Maganin CAR-T na Asibitin Lu Daopei Ƙananan Ƙididdigar CD19 yana Nuna Sakamako masu Alkawari a cikin B-ALL marasa lafiya
Wani bincike na baya-bayan nan a asibitin Lu Daopei ya nuna babban inganci da aminci na ƙananan ƙwayoyin CD19 CAR-T a cikin kula da marasa lafiya na lymphoblastic cutar sankarar bargo (B-ALL). Binciken, wanda ya haɗa da marasa lafiya 51, ya nuna cikakkiyar adadin gafara tare da ƙananan sakamako masu illa.
Dabarun Promoter Novel Yana Haɓaka Aminci da Ingantaccen Maganin CAR-T a cikin Cutar sankarar ƙwayar cuta B Cell
Asibitin Lu Daopei da Hebei Senlang Biotechnology sun ba da sanarwar sakamako masu ban sha'awa daga binciken da suka yi a baya-bayan nan kan aminci da ingancin maganin CAR-T don cutar sankarar ƙwayar cuta ta B cell. Wannan haɗin gwiwar yana nuna yuwuwar ƙirar sabbin ƙwayoyin CAR-T don haɓaka sakamakon haƙuri.
Nazarin Nazari Yana Nuna Aminci da Ingantattun Magungunan CAR-T wajen Magance Malignancies na B-Cell
Wani sabon binciken da Dr. Zhi-tao Ying ya jagoranta daga Asibitin Ciwon daji na Jami'ar Peking ya nuna aminci da inganci na IM19 CAR-T tantanin halitta a cikin maganin sake dawowa da cututtukan cututtukan jini na B-cell. An buga a cikinJaridar Sinawa ta Sabbin Magunguna, Binciken ya ba da rahoton cewa 11 daga cikin marasa lafiya na 12 sun sami cikakkiyar gafara ba tare da mummunar tasiri ba, suna nuna yiwuwar IM19 a matsayin zaɓi na magani mai ban sha'awa ga marasa lafiya tare da iyakacin iyaka.
An Gudanar Da Koyarwar Fasahar Kula da Jini na Shekara-shekara a Asibitin Yanda Ludaopei
Horarwar Shekara-shekara na 2024 don Kula da Jini na Clinical da Fasahar Canjawa a Garin Sanhe an yi nasarar gudanar da shi a Asibitin Yanda Ludaopei. Wannan taron yana da nufin haɓaka aikin kula da jini na asibiti da amincin jini ta hanyar cikakken zaman horo wanda sama da 100 kwararrun kiwon lafiya suka halarta daga cibiyoyin kiwon lafiya daban-daban.
Haɓaka Lafiya da Farfaɗowa: Kulawa na yau da kullun ga masu cutar sankarar bargo
Tabbatar da amintaccen ƙwarewar jiyya ga masu cutar sankarar bargo ya haɗa da kulawa ta yau da kullun, gami da tsabtace muhalli, tsaftar mutum, abinci mai gina jiki, da motsa jiki mai dacewa. Wannan jagorar yana ba da mahimman shawarwari don ingantaccen kulawar yau da kullun don tallafawa farfadowa.
NS7CAR-T Magungunan Kwayoyin Kwayoyin Yana Nuna Alkawari don Magance R/R T-ALL/LBL
Wani bincike na baya-bayan nan ya nuna inganci da aminci na NS7CAR-T cell far a cikin zalunta relapsed ko refractory T-cell m lymphoblastic cutar sankarar bargo (R/R T-ALL) da kuma T-cell lymphoblastic lymphoma (R/R T-LBL). Wannan farfadowa yana ba da sabon bege ga marasa lafiya da waɗannan nau'ikan ciwon daji masu tsanani.
Sanarwa da 2024 Annual Lu Daopei Hematology Forum a watan Agusta
An shirya taron shekara-shekara na Lu Daopei na shekara-shekara karo na 12 daga ranar 23 zuwa 24 ga Agusta, 2024, a cibiyar taron kasa da kasa ta birnin Beijing. Kasance tare da mu don tattaunawa mai ma'ana da sabbin ci gaba a ilimin jini.